Sign In
Buy ABUS
$4.35
+0.0900 (+2.11%)
At Close: Jun 03, 2026
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:30am, Wednesday, 13'th May 2026
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
07:30am, Wednesday, 15'th Apr 2026
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABU
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
07:30am, Monday, 23'rd Mar 2026
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
04:46pm, Tuesday, 03'rd Mar 2026
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Cir
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts
07:48am, Tuesday, 03'rd Feb 2026
Arbutus Biotech faces a pivotal March jury trial against Moderna over LNP patent infringement, creating significant legal optionality. ABUS's valuation is driven by its hepatitis B pipeline, especiall
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 12'th Jan 2026
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:30am, Thursday, 13'th Nov 2025
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-Bi
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
08:00am, Tuesday, 07'th Oct 2025
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
10:41am, Friday, 03'rd Oct 2025
Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
10:41am, Monday, 01'st Sep 2025
Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.
Arbutus (ABUS) Q2 Revenue Surges 529%
02:48pm, Wednesday, 06'th Aug 2025
Arbutus (ABUS) Q2 Revenue Surges 529%
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
09:41am, Wednesday, 06'th Aug 2025
Arbutus Biopharma (ABUS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.11 per share a year ago.
